soul trial oral semaglutide cardiovascular outcomes results 2025 nejm 🧿 is the first oral GLP-1 RA proven to reduce MACE in high-risk T2DM patients, extending protection beyond injectable formulations. Trial: Oral Semaglutide & Cardiovascular in T2DM In patients with type 2

Locks in hydration

As of 2025, Ozempic 2.0 has not yet received full FDA approval, but it is currently in the late stages of clinical evaluation, showing strong progress in studies focused on improved weight loss, better glycemic control, and reduced gastrointestinal side effects

Lower stress levels can lead to fewer skin breakouts and a more balanced, even complexion, contributing to fair skin

That's based on research involving rats, however, and no studies done on humans have established the same connection

The ketogenic diet has also emerged as a powerful alternative that helps patients achieve substantial weight reduction through a high-fat, low-carbohydrate approach